Neoparin (Enoxaparin Sodium)

Enoxaparin Sodium, the active ingredient in Neoparin, is a low molecular weight heparin presented as a sterile solution for subcutaneous and intravenous use. It is used to prevent and treat venous thromboembolism in adult patients at risk of clot formation.

GNH USA supplies Neoparin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neoparin (enoxaparin sodium) is employed in the management of thromboembolic disorders and related procedural anticoagulation. - Deep vein thrombosis prophylaxis: reduces the incidence of DVT in surgical and medically immobilized patients. - Deep vein thrombosis treatment: facilitates clot resolution and prevents extension in acute DVT. - Pulmonary embolism prevention and treatment: provides anticoagulation to avert or manage PE events. - Anticoagulation during hemodialysis or extracorporeal procedures: maintains circuit patency by inhibiting clot formation.

Neoparin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site erythema or bruising - Minor bleeding (e.g., gum, nosebleeds) - Nausea - Elevated liver enzymes

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal) - Heparin‑induced thrombocytopenia (HIT) - Allergic reactions including anaphylaxis - Spinal or epidural hematoma (with neuraxial procedures)

When using Neoparin, clinicians should observe several safety considerations to minimize risk. - Renal function: adjust dose or avoid in severe renal impairment (creatinine clearance <30 mL/min). - Bleeding risk: evaluate for active bleeding, recent surgery, or coagulopathy before initiation. - Concomitant anticoagulants: avoid simultaneous use with other anticoagulants unless specifically indicated. - Pregnancy and lactation: use only if the potential benefit outweighs the potential risk, as safety data are limited. - Monitoring: assess platelet counts periodically to detect heparin‑induced thrombocytopenia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Neoparin can interact with other medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct thrombin inhibitors) – may cause uncontrolled bleeding. - Neuraxial anesthesia or spinal puncture – heightened risk of spinal hematoma. - Known heparin‑induced thrombocytopenia – contraindicated due to cross‑reactivity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or antiplatelet agents – increase bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic drugs – may potentiate hemorrhagic risk. - ACE inhibitors or angiotensin receptor blockers – may enhance anticoagulant effect in some patients. - Renal‑clearing drugs (e.g., aminoglycosides) – may require dose adjustment of enoxaparin.